Jeffrey Skolnik of Inovio Pharmaceuticals Inc. Discusses Glioblastoma Treatment

June 02, 2020

Jeffrey Skolnik, MD, vice president, clinical development of Inovio Pharmaceuticals Inc Discusses Glioblastoma Treatment in ASCO interview.

AstraZeneca's Adrian Kilcoyne Claims Paradigm Shift in Lung Cancer Treatment

June 02, 2020

Adrian Kilcoyne MD MBA MPH, vice president, US Medical Affairs and HEOR, oncology, AstraZeneca, discusses a paradigm shift in lung cancer treatment due to the overwhelming efficacy of the EGFR-TKI treatment.

AstraZeneca’s Tagrisso Keeps Most Lung Cancer Patients With Mutation Alive Two Years After Surgery

June 01, 2020

Tagrisso, the targeted therapy made by AstraZeneca, could become the treatment of choice for the majority of lung cancer patients with mutations in a certain gene who are treated after surgery, based on findings presented this past weekend at the American Society of Clinical Oncology annual meeting.

Keytruda Doubles Progression-Free Survival for Colorectal Cancer Patients with Mutation

June 01, 2020

Keytruda, the immunotherapy with more than 20 indications in both blood and solid tumor cancers, doubled rates of progression-free survival for certain patients with metastatic colorectal cancer, according to results presented Sunday at the American Society of Clinical Oncology annual meeting.

Flatiron Health’s Dr. Bobby Green Outlines Novel Clinical Trial to Understand Genomic Changes in Tumors (VIDEO)

May 31, 2020

During the American Society of Clinical Oncology 2020 Annual Meeting, Flatiron Health, Foundation Medicine, and Genentech will be presenting plans for the Prospective Clinico-Genomic study (PCG), a low-interventional pilot that will use a technology-enabled prospective data collection platform to simplify data collection for patients with lung cancer being treated through clinical trials. The idea is collect blood samples using Foundation Medicine’s liquid biopsy assay and analyze the results through Flatiron’s platform, to see if genomic changes can be detected over the course of cancer treatment. Bobby Green, MD, chief medical officer for Flatiron Health, spoke with Managed Healthcare Executive®.

Anna Lee Shares ASCO Study on Changes in Cancer Mortality Rates (VIDEO)

May 29, 2020

Anna Lee, lead author of the abstract: Changes in Cancer Mortality Rates After the Adoption of the Affordable Care Act, discusses her study with MHE. Lee presented her study May 29 during ASCO 2020's virtual conference.

Sara Douglas Discusses ASCO Study on Distance Caregiving (VIDEO)

May 29, 2020

Sara Douglas, lead investigator of the Abstract: Video Conference Intervention for Distance Caregivers (DCGs) of Patients with Cancer: Improving Psychological Outcomes, discusses her study with MHE's Briana Contreras which will be presented at ASCO 2020.

MURANO Shows Worse Outcomes in R/R CLL When Venetoclax is Stopped Early

May 29, 2020

A fresh look at MURANO data, released this week at the American Society of Clinical Oncology 2020 Annual meeting, shows the poor outcomes that result when patients halt treatment for good, and highlight the need to manage doses carefully to avoid toxicity.

Taking Aim at TIGIT, a New Immunotherapy Approach to Non-Small Cell Lung Cancer

May 29, 2020

The 2020 annual meeting of the American Society of Clinical Oncology that launches today will feature the first results from CITYSCAPE, a trial involving a novel immunotherapy approach in non-small cell lung cancer (NSCLC). This phase 2 trial is the first to combine the immunotherapy tiragolumab with atelzolizumab (Tecentriq), the monoclonal antibody that targets the programmed cell death ligand-1 (PD-L1).